Global Quadrivalent Flu Vaccine Market

Quadrivalent Flu Vaccine Comprehensive Study by Type (Intramuscular Injection, Nasal Spray, Intradermal Shot), Application (Hospital, Clinic, Public Health Agency, Other), Age Group (Adults, Pediatrics) Players and Region - Global Market Outlook to 2026

Quadrivalent Flu Vaccine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Quadrivalent Flu Vaccine Market Overview:
The quadrivalent flu vaccine is designed to protect against four different flu viruses such as two influenzas A viruses and two influenza B viruses. Different vaccines are approved for different age groups. There is a quadrivalent flu shot that can be given to children as young as sixth months of age. Other quadrivalent flu shots are approved for people three years and older.

Growth Drivers
  • Growing Health Awareness across the Globe
  • The Increasing Flu Prevalence Worldwide

Roadblocks
  • High Manufacturing Cost Involved in Adult Vaccines
  • Stringent Regulatory Guidelines

Opportunities
  • Rising Demand from Emerging Countries
  • World Health Organization (WHO) Favorable Initiatives

Challenges
  • High Cost Involved in Research and Development


Competitive Landscape:

Some of the key players profiled in the report are AstraZeneca (United Kingdom), CSL Limited (Australia), GlaxoSmithKline (United Kingdom), Sanofi (France), Altimmune (United States), BionVax (Israel), FluGen (United States), FOLIA BIOTECH Inc. (Canada), Novavax (United States) and SK Chemicals (South Korea). Additionally, following companies can also be profiled that are part of our coverage like Shijiazhuang Yiling Pharmaceutical (China), Vaccitech (United Kingdom) and Vaxine Pty (Australia). Analyst at AMA Research see United States and United Kingdom Players to retain maximum share of Global Quadrivalent Flu Vaccine market by 2026. Considering Market by Age Group, the sub-segment i.e. Adults will boost the Quadrivalent Flu Vaccine market.

On 15 July 2019, GSK announced that it will begin shipping its quadrivalent influenza vaccines to United States healthcare providers and pharmacies for the 2019-20 flu season, immediately following licensing and lot-release approval from the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research.

What Can be Explored with the Quadrivalent Flu Vaccine Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Quadrivalent Flu Vaccine Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Quadrivalent Flu Vaccine
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Quadrivalent Flu Vaccine market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Quadrivalent Flu Vaccine market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Quadrivalent Flu Vaccine Manufacturers, Quadrivalent Flu Vaccine Traders/Distributors, Quadrivalent Flu Vaccine Importer/Exporter, Regulatory & Government Bodies, Research & Consulting Firms, End Users and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Intramuscular Injection
  • Nasal Spray
  • Intradermal Shot
By Application
  • Hospital
  • Clinic
  • Public Health Agency
  • Other
By Age Group
  • Adults
  • Pediatrics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Health Awareness across the Globe
      • 3.2.2. The Increasing Flu Prevalence Worldwide
    • 3.3. Market Challenges
      • 3.3.1. High Cost Involved in Research and Development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Quadrivalent Flu Vaccine, by Type, Application, Age Group and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Quadrivalent Flu Vaccine (Value)
      • 5.2.1. Global Quadrivalent Flu Vaccine by: Type (Value)
        • 5.2.1.1. Intramuscular Injection
        • 5.2.1.2. Nasal Spray
        • 5.2.1.3. Intradermal Shot
      • 5.2.2. Global Quadrivalent Flu Vaccine by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Public Health Agency
        • 5.2.2.4. Other
      • 5.2.3. Global Quadrivalent Flu Vaccine by: Age Group (Value)
        • 5.2.3.1. Adults
        • 5.2.3.2. Pediatrics
      • 5.2.4. Global Quadrivalent Flu Vaccine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Quadrivalent Flu Vaccine (Volume)
      • 5.3.1. Global Quadrivalent Flu Vaccine by: Type (Volume)
        • 5.3.1.1. Intramuscular Injection
        • 5.3.1.2. Nasal Spray
        • 5.3.1.3. Intradermal Shot
      • 5.3.2. Global Quadrivalent Flu Vaccine by: Application (Volume)
        • 5.3.2.1. Hospital
        • 5.3.2.2. Clinic
        • 5.3.2.3. Public Health Agency
        • 5.3.2.4. Other
      • 5.3.3. Global Quadrivalent Flu Vaccine by: Age Group (Volume)
        • 5.3.3.1. Adults
        • 5.3.3.2. Pediatrics
      • 5.3.4. Global Quadrivalent Flu Vaccine Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Quadrivalent Flu Vaccine (Price)
      • 5.4.1. Global Quadrivalent Flu Vaccine by: Type (Price)
  • 6. Quadrivalent Flu Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. CSL Limited (Australia)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Altimmune (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. BionVax (Israel)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. FluGen (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. FOLIA BIOTECH Inc. (Canada)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novavax (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. SK Chemicals (South Korea)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Quadrivalent Flu Vaccine Sale, by Type, Application, Age Group and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Quadrivalent Flu Vaccine (Value)
      • 7.2.1. Global Quadrivalent Flu Vaccine by: Type (Value)
        • 7.2.1.1. Intramuscular Injection
        • 7.2.1.2. Nasal Spray
        • 7.2.1.3. Intradermal Shot
      • 7.2.2. Global Quadrivalent Flu Vaccine by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Public Health Agency
        • 7.2.2.4. Other
      • 7.2.3. Global Quadrivalent Flu Vaccine by: Age Group (Value)
        • 7.2.3.1. Adults
        • 7.2.3.2. Pediatrics
      • 7.2.4. Global Quadrivalent Flu Vaccine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Quadrivalent Flu Vaccine (Volume)
      • 7.3.1. Global Quadrivalent Flu Vaccine by: Type (Volume)
        • 7.3.1.1. Intramuscular Injection
        • 7.3.1.2. Nasal Spray
        • 7.3.1.3. Intradermal Shot
      • 7.3.2. Global Quadrivalent Flu Vaccine by: Application (Volume)
        • 7.3.2.1. Hospital
        • 7.3.2.2. Clinic
        • 7.3.2.3. Public Health Agency
        • 7.3.2.4. Other
      • 7.3.3. Global Quadrivalent Flu Vaccine by: Age Group (Volume)
        • 7.3.3.1. Adults
        • 7.3.3.2. Pediatrics
      • 7.3.4. Global Quadrivalent Flu Vaccine Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Quadrivalent Flu Vaccine (Price)
      • 7.4.1. Global Quadrivalent Flu Vaccine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Quadrivalent Flu Vaccine: by Type(USD Million)
  • Table 2. Quadrivalent Flu Vaccine Intramuscular Injection , by Region USD Million (2015-2020)
  • Table 3. Quadrivalent Flu Vaccine Nasal Spray , by Region USD Million (2015-2020)
  • Table 4. Quadrivalent Flu Vaccine Intradermal Shot , by Region USD Million (2015-2020)
  • Table 5. Quadrivalent Flu Vaccine: by Application(USD Million)
  • Table 6. Quadrivalent Flu Vaccine Hospital , by Region USD Million (2015-2020)
  • Table 7. Quadrivalent Flu Vaccine Clinic , by Region USD Million (2015-2020)
  • Table 8. Quadrivalent Flu Vaccine Public Health Agency , by Region USD Million (2015-2020)
  • Table 9. Quadrivalent Flu Vaccine Other , by Region USD Million (2015-2020)
  • Table 10. Quadrivalent Flu Vaccine: by Age Group(USD Million)
  • Table 11. Quadrivalent Flu Vaccine Adults , by Region USD Million (2015-2020)
  • Table 12. Quadrivalent Flu Vaccine Pediatrics , by Region USD Million (2015-2020)
  • Table 13. South America Quadrivalent Flu Vaccine, by Country USD Million (2015-2020)
  • Table 14. South America Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 15. South America Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 16. South America Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 17. Brazil Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 18. Brazil Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 19. Brazil Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 20. Argentina Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 21. Argentina Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 22. Argentina Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 23. Rest of South America Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 24. Rest of South America Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 25. Rest of South America Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 26. Asia Pacific Quadrivalent Flu Vaccine, by Country USD Million (2015-2020)
  • Table 27. Asia Pacific Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 28. Asia Pacific Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 29. Asia Pacific Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 30. China Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 31. China Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 32. China Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 33. Japan Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 34. Japan Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 35. Japan Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 36. India Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 37. India Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 38. India Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 39. South Korea Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 40. South Korea Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 41. South Korea Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 42. Taiwan Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 43. Taiwan Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 44. Taiwan Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 45. Australia Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 46. Australia Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 47. Australia Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 51. Europe Quadrivalent Flu Vaccine, by Country USD Million (2015-2020)
  • Table 52. Europe Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 53. Europe Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 54. Europe Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 55. Germany Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 56. Germany Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 57. Germany Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 58. France Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 59. France Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 60. France Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 61. Italy Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 62. Italy Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 63. Italy Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 64. United Kingdom Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 65. United Kingdom Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 66. United Kingdom Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 67. Netherlands Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 68. Netherlands Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 69. Netherlands Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 70. Rest of Europe Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 71. Rest of Europe Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 72. Rest of Europe Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 73. MEA Quadrivalent Flu Vaccine, by Country USD Million (2015-2020)
  • Table 74. MEA Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 75. MEA Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 76. MEA Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 77. Middle East Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 78. Middle East Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 79. Middle East Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 80. Africa Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 81. Africa Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 82. Africa Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 83. North America Quadrivalent Flu Vaccine, by Country USD Million (2015-2020)
  • Table 84. North America Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 85. North America Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 86. North America Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 87. United States Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 88. United States Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 89. United States Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 90. Canada Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 91. Canada Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 92. Canada Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 93. Mexico Quadrivalent Flu Vaccine, by Type USD Million (2015-2020)
  • Table 94. Mexico Quadrivalent Flu Vaccine, by Application USD Million (2015-2020)
  • Table 95. Mexico Quadrivalent Flu Vaccine, by Age Group USD Million (2015-2020)
  • Table 96. Quadrivalent Flu Vaccine Sales: by Type(K Units)
  • Table 97. Quadrivalent Flu Vaccine Sales Intramuscular Injection , by Region K Units (2015-2020)
  • Table 98. Quadrivalent Flu Vaccine Sales Nasal Spray , by Region K Units (2015-2020)
  • Table 99. Quadrivalent Flu Vaccine Sales Intradermal Shot , by Region K Units (2015-2020)
  • Table 100. Quadrivalent Flu Vaccine Sales: by Application(K Units)
  • Table 101. Quadrivalent Flu Vaccine Sales Hospital , by Region K Units (2015-2020)
  • Table 102. Quadrivalent Flu Vaccine Sales Clinic , by Region K Units (2015-2020)
  • Table 103. Quadrivalent Flu Vaccine Sales Public Health Agency , by Region K Units (2015-2020)
  • Table 104. Quadrivalent Flu Vaccine Sales Other , by Region K Units (2015-2020)
  • Table 105. Quadrivalent Flu Vaccine Sales: by Age Group(K Units)
  • Table 106. Quadrivalent Flu Vaccine Sales Adults , by Region K Units (2015-2020)
  • Table 107. Quadrivalent Flu Vaccine Sales Pediatrics , by Region K Units (2015-2020)
  • Table 108. South America Quadrivalent Flu Vaccine Sales, by Country K Units (2015-2020)
  • Table 109. South America Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 110. South America Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 111. South America Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 112. Brazil Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 113. Brazil Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 114. Brazil Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 115. Argentina Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 116. Argentina Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 117. Argentina Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 118. Rest of South America Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 119. Rest of South America Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 120. Rest of South America Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 121. Asia Pacific Quadrivalent Flu Vaccine Sales, by Country K Units (2015-2020)
  • Table 122. Asia Pacific Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 123. Asia Pacific Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 124. Asia Pacific Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 125. China Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 126. China Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 127. China Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 128. Japan Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 129. Japan Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 130. Japan Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 131. India Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 132. India Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 133. India Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 134. South Korea Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 135. South Korea Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 136. South Korea Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 137. Taiwan Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 138. Taiwan Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 139. Taiwan Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 140. Australia Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 141. Australia Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 142. Australia Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 143. Rest of Asia-Pacific Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 144. Rest of Asia-Pacific Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 145. Rest of Asia-Pacific Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 146. Europe Quadrivalent Flu Vaccine Sales, by Country K Units (2015-2020)
  • Table 147. Europe Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 148. Europe Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 149. Europe Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 150. Germany Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 151. Germany Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 152. Germany Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 153. France Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 154. France Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 155. France Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 156. Italy Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 157. Italy Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 158. Italy Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 159. United Kingdom Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 160. United Kingdom Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 161. United Kingdom Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 162. Netherlands Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 163. Netherlands Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 164. Netherlands Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 165. Rest of Europe Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 166. Rest of Europe Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 167. Rest of Europe Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 168. MEA Quadrivalent Flu Vaccine Sales, by Country K Units (2015-2020)
  • Table 169. MEA Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 170. MEA Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 171. MEA Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 172. Middle East Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 173. Middle East Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 174. Middle East Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 175. Africa Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 176. Africa Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 177. Africa Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 178. North America Quadrivalent Flu Vaccine Sales, by Country K Units (2015-2020)
  • Table 179. North America Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 180. North America Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 181. North America Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 182. United States Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 183. United States Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 184. United States Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 185. Canada Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 186. Canada Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 187. Canada Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 188. Mexico Quadrivalent Flu Vaccine Sales, by Type K Units (2015-2020)
  • Table 189. Mexico Quadrivalent Flu Vaccine Sales, by Application K Units (2015-2020)
  • Table 190. Mexico Quadrivalent Flu Vaccine Sales, by Age Group K Units (2015-2020)
  • Table 191. Quadrivalent Flu Vaccine: by Type(USD/Units)
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Quadrivalent Flu Vaccine: by Type(USD Million)
  • Table 203. Quadrivalent Flu Vaccine Intramuscular Injection , by Region USD Million (2021-2026)
  • Table 204. Quadrivalent Flu Vaccine Nasal Spray , by Region USD Million (2021-2026)
  • Table 205. Quadrivalent Flu Vaccine Intradermal Shot , by Region USD Million (2021-2026)
  • Table 206. Quadrivalent Flu Vaccine: by Application(USD Million)
  • Table 207. Quadrivalent Flu Vaccine Hospital , by Region USD Million (2021-2026)
  • Table 208. Quadrivalent Flu Vaccine Clinic , by Region USD Million (2021-2026)
  • Table 209. Quadrivalent Flu Vaccine Public Health Agency , by Region USD Million (2021-2026)
  • Table 210. Quadrivalent Flu Vaccine Other , by Region USD Million (2021-2026)
  • Table 211. Quadrivalent Flu Vaccine: by Age Group(USD Million)
  • Table 212. Quadrivalent Flu Vaccine Adults , by Region USD Million (2021-2026)
  • Table 213. Quadrivalent Flu Vaccine Pediatrics , by Region USD Million (2021-2026)
  • Table 214. South America Quadrivalent Flu Vaccine, by Country USD Million (2021-2026)
  • Table 215. South America Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 216. South America Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 217. South America Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 218. Brazil Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 219. Brazil Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 220. Brazil Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 221. Argentina Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 222. Argentina Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 223. Argentina Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 224. Rest of South America Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 225. Rest of South America Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 226. Rest of South America Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 227. Asia Pacific Quadrivalent Flu Vaccine, by Country USD Million (2021-2026)
  • Table 228. Asia Pacific Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 229. Asia Pacific Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 230. Asia Pacific Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 231. China Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 232. China Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 233. China Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 234. Japan Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 235. Japan Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 236. Japan Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 237. India Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 238. India Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 239. India Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 240. South Korea Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 241. South Korea Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 242. South Korea Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 243. Taiwan Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 244. Taiwan Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 245. Taiwan Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 246. Australia Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 247. Australia Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 248. Australia Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 249. Rest of Asia-Pacific Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 250. Rest of Asia-Pacific Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 251. Rest of Asia-Pacific Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 252. Europe Quadrivalent Flu Vaccine, by Country USD Million (2021-2026)
  • Table 253. Europe Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 254. Europe Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 255. Europe Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 256. Germany Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 257. Germany Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 258. Germany Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 259. France Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 260. France Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 261. France Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 262. Italy Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 263. Italy Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 264. Italy Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 265. United Kingdom Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 266. United Kingdom Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 267. United Kingdom Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 268. Netherlands Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 269. Netherlands Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 270. Netherlands Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 271. Rest of Europe Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 272. Rest of Europe Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 273. Rest of Europe Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 274. MEA Quadrivalent Flu Vaccine, by Country USD Million (2021-2026)
  • Table 275. MEA Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 276. MEA Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 277. MEA Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 278. Middle East Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 279. Middle East Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 280. Middle East Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 281. Africa Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 282. Africa Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 283. Africa Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 284. North America Quadrivalent Flu Vaccine, by Country USD Million (2021-2026)
  • Table 285. North America Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 286. North America Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 287. North America Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 288. United States Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 289. United States Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 290. United States Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 291. Canada Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 292. Canada Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 293. Canada Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 294. Mexico Quadrivalent Flu Vaccine, by Type USD Million (2021-2026)
  • Table 295. Mexico Quadrivalent Flu Vaccine, by Application USD Million (2021-2026)
  • Table 296. Mexico Quadrivalent Flu Vaccine, by Age Group USD Million (2021-2026)
  • Table 297. Quadrivalent Flu Vaccine Sales: by Type(K Units)
  • Table 298. Quadrivalent Flu Vaccine Sales Intramuscular Injection , by Region K Units (2021-2026)
  • Table 299. Quadrivalent Flu Vaccine Sales Nasal Spray , by Region K Units (2021-2026)
  • Table 300. Quadrivalent Flu Vaccine Sales Intradermal Shot , by Region K Units (2021-2026)
  • Table 301. Quadrivalent Flu Vaccine Sales: by Application(K Units)
  • Table 302. Quadrivalent Flu Vaccine Sales Hospital , by Region K Units (2021-2026)
  • Table 303. Quadrivalent Flu Vaccine Sales Clinic , by Region K Units (2021-2026)
  • Table 304. Quadrivalent Flu Vaccine Sales Public Health Agency , by Region K Units (2021-2026)
  • Table 305. Quadrivalent Flu Vaccine Sales Other , by Region K Units (2021-2026)
  • Table 306. Quadrivalent Flu Vaccine Sales: by Age Group(K Units)
  • Table 307. Quadrivalent Flu Vaccine Sales Adults , by Region K Units (2021-2026)
  • Table 308. Quadrivalent Flu Vaccine Sales Pediatrics , by Region K Units (2021-2026)
  • Table 309. South America Quadrivalent Flu Vaccine Sales, by Country K Units (2021-2026)
  • Table 310. South America Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 311. South America Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 312. South America Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 313. Brazil Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 314. Brazil Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 315. Brazil Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 316. Argentina Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 317. Argentina Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 318. Argentina Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 319. Rest of South America Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 320. Rest of South America Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 321. Rest of South America Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 322. Asia Pacific Quadrivalent Flu Vaccine Sales, by Country K Units (2021-2026)
  • Table 323. Asia Pacific Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 324. Asia Pacific Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 325. Asia Pacific Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 326. China Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 327. China Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 328. China Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 329. Japan Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 330. Japan Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 331. Japan Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 332. India Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 333. India Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 334. India Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 335. South Korea Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 336. South Korea Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 337. South Korea Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 338. Taiwan Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 339. Taiwan Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 340. Taiwan Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 341. Australia Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 342. Australia Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 343. Australia Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 344. Rest of Asia-Pacific Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 345. Rest of Asia-Pacific Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 346. Rest of Asia-Pacific Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 347. Europe Quadrivalent Flu Vaccine Sales, by Country K Units (2021-2026)
  • Table 348. Europe Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 349. Europe Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 350. Europe Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 351. Germany Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 352. Germany Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 353. Germany Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 354. France Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 355. France Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 356. France Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 357. Italy Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 358. Italy Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 359. Italy Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 360. United Kingdom Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 361. United Kingdom Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 362. United Kingdom Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 363. Netherlands Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 364. Netherlands Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 365. Netherlands Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 366. Rest of Europe Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 367. Rest of Europe Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 368. Rest of Europe Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 369. MEA Quadrivalent Flu Vaccine Sales, by Country K Units (2021-2026)
  • Table 370. MEA Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 371. MEA Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 372. MEA Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 373. Middle East Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 374. Middle East Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 375. Middle East Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 376. Africa Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 377. Africa Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 378. Africa Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 379. North America Quadrivalent Flu Vaccine Sales, by Country K Units (2021-2026)
  • Table 380. North America Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 381. North America Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 382. North America Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 383. United States Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 384. United States Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 385. United States Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 386. Canada Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 387. Canada Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 388. Canada Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 389. Mexico Quadrivalent Flu Vaccine Sales, by Type K Units (2021-2026)
  • Table 390. Mexico Quadrivalent Flu Vaccine Sales, by Application K Units (2021-2026)
  • Table 391. Mexico Quadrivalent Flu Vaccine Sales, by Age Group K Units (2021-2026)
  • Table 392. Quadrivalent Flu Vaccine: by Type(USD/Units)
  • Table 393. Research Programs/Design for This Report
  • Table 394. Key Data Information from Secondary Sources
  • Table 395. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Quadrivalent Flu Vaccine: by Type USD Million (2015-2020)
  • Figure 5. Global Quadrivalent Flu Vaccine: by Application USD Million (2015-2020)
  • Figure 6. Global Quadrivalent Flu Vaccine: by Age Group USD Million (2015-2020)
  • Figure 7. South America Quadrivalent Flu Vaccine Share (%), by Country
  • Figure 8. Asia Pacific Quadrivalent Flu Vaccine Share (%), by Country
  • Figure 9. Europe Quadrivalent Flu Vaccine Share (%), by Country
  • Figure 10. MEA Quadrivalent Flu Vaccine Share (%), by Country
  • Figure 11. North America Quadrivalent Flu Vaccine Share (%), by Country
  • Figure 12. Global Quadrivalent Flu Vaccine: by Type K Units (2015-2020)
  • Figure 13. Global Quadrivalent Flu Vaccine: by Application K Units (2015-2020)
  • Figure 14. Global Quadrivalent Flu Vaccine: by Age Group K Units (2015-2020)
  • Figure 15. South America Quadrivalent Flu Vaccine Share (%), by Country
  • Figure 16. Asia Pacific Quadrivalent Flu Vaccine Share (%), by Country
  • Figure 17. Europe Quadrivalent Flu Vaccine Share (%), by Country
  • Figure 18. MEA Quadrivalent Flu Vaccine Share (%), by Country
  • Figure 19. North America Quadrivalent Flu Vaccine Share (%), by Country
  • Figure 20. Global Quadrivalent Flu Vaccine: by Type USD/Units (2015-2020)
  • Figure 21. Global Quadrivalent Flu Vaccine share by Players 2020 (%)
  • Figure 22. Global Quadrivalent Flu Vaccine share by Players (Top 3) 2020(%)
  • Figure 23. Global Quadrivalent Flu Vaccine share by Players (Top 5) 2020(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 27. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 28. CSL Limited (Australia) Revenue: by Geography 2020
  • Figure 29. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 31. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 32. Sanofi (France) Revenue: by Geography 2020
  • Figure 33. Altimmune (United States) Revenue, Net Income and Gross profit
  • Figure 34. Altimmune (United States) Revenue: by Geography 2020
  • Figure 35. BionVax (Israel) Revenue, Net Income and Gross profit
  • Figure 36. BionVax (Israel) Revenue: by Geography 2020
  • Figure 37. FluGen (United States) Revenue, Net Income and Gross profit
  • Figure 38. FluGen (United States) Revenue: by Geography 2020
  • Figure 39. FOLIA BIOTECH Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 40. FOLIA BIOTECH Inc. (Canada) Revenue: by Geography 2020
  • Figure 41. Novavax (United States) Revenue, Net Income and Gross profit
  • Figure 42. Novavax (United States) Revenue: by Geography 2020
  • Figure 43. SK Chemicals (South Korea) Revenue, Net Income and Gross profit
  • Figure 44. SK Chemicals (South Korea) Revenue: by Geography 2020
  • Figure 45. Global Quadrivalent Flu Vaccine: by Type USD Million (2021-2026)
  • Figure 46. Global Quadrivalent Flu Vaccine: by Application USD Million (2021-2026)
  • Figure 47. Global Quadrivalent Flu Vaccine: by Age Group USD Million (2021-2026)
  • Figure 48. South America Quadrivalent Flu Vaccine Share (%), by Country
  • Figure 49. Asia Pacific Quadrivalent Flu Vaccine Share (%), by Country
  • Figure 50. Europe Quadrivalent Flu Vaccine Share (%), by Country
  • Figure 51. MEA Quadrivalent Flu Vaccine Share (%), by Country
  • Figure 52. North America Quadrivalent Flu Vaccine Share (%), by Country
  • Figure 53. Global Quadrivalent Flu Vaccine: by Type K Units (2021-2026)
  • Figure 54. Global Quadrivalent Flu Vaccine: by Application K Units (2021-2026)
  • Figure 55. Global Quadrivalent Flu Vaccine: by Age Group K Units (2021-2026)
  • Figure 56. South America Quadrivalent Flu Vaccine Share (%), by Country
  • Figure 57. Asia Pacific Quadrivalent Flu Vaccine Share (%), by Country
  • Figure 58. Europe Quadrivalent Flu Vaccine Share (%), by Country
  • Figure 59. MEA Quadrivalent Flu Vaccine Share (%), by Country
  • Figure 60. North America Quadrivalent Flu Vaccine Share (%), by Country
  • Figure 61. Global Quadrivalent Flu Vaccine: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • AstraZeneca (United Kingdom)
  • CSL Limited (Australia)
  • GlaxoSmithKline (United Kingdom)
  • Sanofi (France)
  • Altimmune (United States)
  • BionVax (Israel)
  • FluGen (United States)
  • FOLIA BIOTECH Inc. (Canada)
  • Novavax (United States)
  • SK Chemicals (South Korea)
Additional players considered in the study are as follows:
Shijiazhuang Yiling Pharmaceutical (China) , Vaccitech (United Kingdom) , Vaxine Pty (Australia)
Select User Access Type

Key Highlights of Report


Aug 2021 246 Pages 54 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Quadrivalent Flu Vaccine Market Quantitative research analysis
Global Quadrivalent Flu Vaccine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Quadrivalent Flu Vaccine market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Quadrivalent Flu Vaccine market are AstraZeneca (United Kingdom), CSL Limited (Australia), GlaxoSmithKline (United Kingdom), Sanofi (France), Altimmune (United States), BionVax (Israel), FluGen (United States), FOLIA BIOTECH Inc. (Canada), Novavax (United States) and SK Chemicals (South Korea), to name a few.

Know More About Global Quadrivalent Flu Vaccine Market Report?

Have a Query? Click Here

Other Related Reports

Spine Osteoarthritis Comprehensive Study by Application (Hospitals and Clinics, Medical Institutes, Research Organization, Others), Treatment (Medication, Surgery, Therapy, Others), Diagnosis (Imagin...
$ 3450
Nasal Polyps Treatment Comprehensive Study by Application (Hospitals, Clinics, Research Center, Other), Treatment (Medications, Surgery), Diagnosis (CT Scan, MRI Scan, Other), Symptoms (Runny Nose, S...
$ 3450
Vitiligo Treatment Comprehensive Study by Type (Topical Treatment, Light Therapy, Surgical Procedures, Others), Application (Hospitals, Aesthetic Clinics, Others), Drugs (ARN-4079, ATI-50001, AX-1602...
$ 3650
Bulimia Nervosa Treatment Comprehensive Study by Therapy (Support group, Cognitive behavioral therapy, Cognitive therapy, Diaelectical behavior therapy, Counseling psychology, Family therapy, Others)...
$ 3750
Scoliosis Management Comprehensive Study by Type (Juvenile Idiopathic Scoliosis, Infantile Idiopathic Scoliosis, Adolescent Idiopathic Scoliosis), Application (Pediatric, Adult), Treatment (Painkilli...
$ 3450
Sleeping Bruxism Treatment Comprehensive Study by Type (Dental Approaches, Medication), Application (Pediatric, Adult), Diagnosis (Clinical Examination, Electromyographic Methods, Polysomnography, X-...
$ 3350